Activated T cells inhibit NK cell-mediated tumour rejection

Scandinavian Journal of Immunology

Volumn 69, Issue 4, 2009, Pages 337-341

  Wang, X J ^a   Hu, J ^a   Yuan, J ^b   Peng, Y M ^a   Gui, L ^a   He, W F ^a   Tan, J ^a   Luo, G X ^a   Wu, J ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b People Hospital of GuiZhou   (China)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER MODEL; CD4+ CD25+ T LYMPHOCYTE; CELL FUNCTION; CONTROLLED STUDY; CYTOKINE RELEASE; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MIXED LYMPHOCYTE CULTURE; MOUSE; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR REJECTION;

ANIMALS; CELL COMMUNICATION; COCULTURE TECHNIQUES; CYTOTOXICITY, IMMUNOLOGIC; IMMUNOLOGIC SURVEILLANCE; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICROSCOPY, CONFOCAL; RATS; RATS, WISTAR; T-LYMPHOCYTES;

EID: 61849169976     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2009.02227.x     Document Type: Article

References (21)

1. Bryceson YT, Long EO. Line of attack: NK cell specificity and integration of signals. Curr Opin Immunol 2008 20 : 344 52.
2. Smyth MJ, Hayakawa Y, Takeda K, Yagita H. New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer 2002 2 : 850 61.
3. Carayannopoulos LN, Yokoyama WM. Recognition of infected cells by natural killer cells. Curr Opin Immunol 2004 16 : 26 33.
4. Chung JW, Yoon SR, Choi I. The regulation of NK cell function and development. Front Biosci 2008 13 : 6432 42.
5. Fehniger TA, Cooper MA, Nuovo GJ et al. CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood 2003 101 : 3052 7.
6. Kasaian MT, Whitters MJ, Carter LL et al. IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity. Immunity 2002 16 : 559 69.
7. Vollmer TL, Liu R, Price M, Rhodes S, La Cava A, Shi FD. Differential effects of IL-21 during initiation and progression of autoimmunity against neuroantigen. J Immunol 2005 174 : 2696 701.
8. Ghiringhelli F, Menard C, Terme M et al. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med 2005 202 : 1075 85.
9. Smyth MJ, Teng MW, Swann J, Kyparissoudis K, Godfrey DI, Hayakawa Y. CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J Immunol 2006 176 : 1582 7.
10. Lehner I, Niehof M, Borlak J. An optimized method for the isolation and identification of membrane proteins. Electrophoresis 2003 24 : 1795 808.
11. Gunzer M, Weishaupt C, Planelles L, Grabbe S. Two-step negative enrichment of CD4+ and CD8+ T cells from murine spleen via nylon wool adherence and an optimized antibody cocktail. J Immunol Methods 2001 258 : 55 63.
12. Faure M, Schmitt D, Dezutter-Dambuyant C, Frappaz A, Gaucherand M, Thivolet J. In vitro studies of epidermal antigen-presenting cells. The mixed skin lymphocyte reaction: an in vitro model for the generation of alloreactive cytotoxic T cells by human epidermal cells. Br J Dermatol 1984 111 (Suppl. 27 11 7.
13. Brunner KT, Mauel J, Cerottini JC, Chapuis B. Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs. Immunology 1968 14 : 181 96.
14. Boldt DH, MacDermott RP, Jorolan EP. Interaction of plant lectins with purified human lymphocyte populations: binding characteristics and kinetics of proliferation. J Immunol 1975 114 : 1532 6.
15. Caligiuri MA, Murray C, Robertson MJ et al. Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2. J Clin Invest 1993 91 : 123 32.
16. Smith KA. Interleukin-2: inception, impact, and implications. Science 1988 240 : 1169 76.
17. Hokari R, Miura S, Fujimori H et al. Altered migration of gut-derived T lymphocytes after activation with concanavalin A. Am J Physiol 1999 277 : G763 72.
18. Leen AM, Rooney CM, Foster AE. Improving T cell therapy for cancer. Annu Rev Immunol 2007 25 : 243 65.
19. Dudley ME, Wunderlich J, Nishimura MI et al. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. 2001 24 : 363 73.
20. Dudley ME, Wunderlich JR, Robbins PF et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002 298 : 850 4.
21. Rosenberg SA, Sherry RM, Morton KE et al. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol 2005 175 : 6169 76.